These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19653573)

  • 1. Modafinil as a potential motion sickness countermeasure.
    Hoyt RE; Lawson BD; McGee HA; Strompolis ML; McClellan MA
    Aviat Space Environ Med; 2009 Aug; 80(8):709-15. PubMed ID: 19653573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Combination of Scopolamine and Psychostimulants for the Prevention of Severe Motion Sickness.
    Zhang LL; Liu HQ; Yu XH; Zhang Y; Tian JS; Song XR; Han B; Liu AJ
    CNS Neurosci Ther; 2016 Aug; 22(8):715-22. PubMed ID: 27160425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel animal model for motion sickness and its first application in rodents.
    Yu XH; Cai GJ; Liu AJ; Chu ZX; Su DF
    Physiol Behav; 2007 Nov; 92(4):702-7. PubMed ID: 17612582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of low-dose intranasal scopolamine for motion sickness.
    Simmons RG; Phillips JB; Lojewski RA; Wang Z; Boyd JL; Putcha L
    Aviat Space Environ Med; 2010 Apr; 81(4):405-12. PubMed ID: 20377145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scopolamine (hyoscine) for preventing and treating motion sickness.
    Spinks AB; Wasiak J; Villanueva EV; Bernath V
    Cochrane Database Syst Rev; 2007 Jul; (3):CD002851. PubMed ID: 17636710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scopolamine (hyoscine) for preventing and treating motion sickness.
    Spinks A; Wasiak J
    Cochrane Database Syst Rev; 2011 Jun; 2011(6):CD002851. PubMed ID: 21678338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scopolamine for preventing and treating motion sickness.
    Spinks AB; Wasiak J; Villanueva EV; Bernath V
    Cochrane Database Syst Rev; 2004; (3):CD002851. PubMed ID: 15266468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate.
    Golding JF; Stott JR
    Br J Clin Pharmacol; 1997 Jun; 43(6):633-7. PubMed ID: 9205824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug treatment of motion sickness: scopolamine alone and combined with ephedrine in real and simulated situations.
    Tokola O; Laitinen LA; Aho J; Gothoni G; Vapaatalo H
    Aviat Space Environ Med; 1984 Jul; 55(7):636-41. PubMed ID: 6466260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.
    Nachum Z; Shupak A; Gordon CR
    Clin Pharmacokinet; 2006; 45(6):543-66. PubMed ID: 16719539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal scopolamine, oral meclizine, and placebo in motion sickness.
    Dahl E; Offer-Ohlsen D; Lillevold PE; Sandvik L
    Clin Pharmacol Ther; 1984 Jul; 36(1):116-20. PubMed ID: 6734040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of antimotion sickness drugs.
    Wood CD; Manno JE; Wood MJ; Manno BR; Redetzki HM
    Aviat Space Environ Med; 1987 Sep; 58(9 Pt 2):A262-5. PubMed ID: 3675502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Various anti-motion sickness drugs and core body temperature changes.
    Cheung B; Nakashima AM; Hofer KD
    Aviat Space Environ Med; 2011 Apr; 82(4):409-15. PubMed ID: 21485398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scopolamine nasal spray in motion sickness: a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo.
    Klöcker N; Hanschke W; Toussaint S; Verse T
    Eur J Pharm Sci; 2001 May; 13(2):227-32. PubMed ID: 11297908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modafinil as a replacement for dextroamphetamine for sustaining alertness in military helicopter pilots.
    Estrada A; Kelley AM; Webb CM; Athy JR; Crowley JS
    Aviat Space Environ Med; 2012 Jun; 83(6):556-64. PubMed ID: 22764609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transdermal scopolamine in the prevention of motion sickness at sea.
    Price NM; Schmitt LG; McGuire J; Shaw JE; Trobough G
    Clin Pharmacol Ther; 1981 Mar; 29(3):414-9. PubMed ID: 7009021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation.
    Swanson JM; Greenhill LL; Lopez FA; Sedillo A; Earl CQ; Jiang JG; Biederman J
    J Clin Psychiatry; 2006 Jan; 67(1):137-47. PubMed ID: 16426100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of transdermally administered scopolamine in preventing motion sickness.
    McCauley ME; Royal JW; Shaw JE; Schmitt LG
    Aviat Space Environ Med; 1979 Nov; 50(11):1108-11. PubMed ID: 393242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the efficacy of cinnarizine with scopolamine in the treatment of seasickness.
    Pingree BJ; Pethybridge RJ
    Aviat Space Environ Med; 1994 Jul; 65(7):597-605. PubMed ID: 7945125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal therapeutic system scopolamine (TTSS), dimenhydrinate, and placebo--a comparative study at sea.
    Noy S; Shapira S; Zilbiger A; Ribak J
    Aviat Space Environ Med; 1984 Nov; 55(11):1051-4. PubMed ID: 6508687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.